Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety/monitoring concepts (narrow therapeutic window, toxicity risk, factors affecting levels, monitoring timing) align with the provided LANOXIN (digoxin) PI excerpts. However, several claims are either too generic to confirm (e.g., bidirectional statements about generic drug regulatory requirements) or contain details not explicitly supported by the provided label excerpts (e.g., specific toxicity symptoms listed like “new severe nausea/vomiting,” “doubling up” wording).
Category Scores
Accurate Statements
Digoxin is used to treat certain heart rhythm and heart failure conditions.
Section 1: HF (mild to moderate in adults) and chronic atrial fibrillation (control of ventricular response rate).
Digoxin is used to slow the heart rate in atrial fibrillation.
Section 1.3: control of ventricular response rate in chronic atrial fibrillation; Section 14.2: reduced resting heart rate.
Digoxin is used to help in some types of heart failure.
Section 1.1: mild to moderate heart failure; also Section 1.7 note to generally avoid in HF with preserved left ventricular systolic function is present but does not negate HF indication.
Digoxin has a narrow therapeutic range such that the difference between effective and toxic levels can be small.
Section 2.1: 'toxic levels... only slightly higher than therapeutic levels.'
Digoxin can cause toxicity if blood levels get too high.
Section 2.1 (toxic only slightly higher); Section 5.3 (toxicity usually associated with levels >2 ng/mL).
Changes in kidney function can affect digoxin levels.
Section 2.1 lists 'renal function' as affecting blood levels; Section 5.3 includes impaired renal function as a predisposition.
Following guidance on monitoring is needed if a clinician orders blood digoxin levels or lab tests.
Section 2.5: monitor for signs/symptoms; obtain serum levels just before next scheduled dose or at least 6 hours after last dose; interpret in clinical context.
Digoxin toxicity can cause symptoms such as confusion.
Section 5.3 includes CNS toxicity (label excerpt indicates 'CNS and other toxicity' in Section 6; and 'signs and symptoms... include...'; CNS examples are not explicitly shown in provided excerpt, so this is only partially supported; see unsupported/omitted for specificity).
Digoxin toxicity can cause significant changes in heart rhythm.
Section 5.3: toxicity includes 'cardiac arrhythmias.'
Unsupported Statements
Generic digoxin is a version of digoxin marketed after the original brand's exclusivity/patent protections allowed generic versions.
Provided label excerpts do not address generic drug marketing, patent/exclusivity history, or timing.
Generic digoxin is expected to match the brand product in key ways required by regulators.
No information on generic regulatory equivalence requirements is present in the supplied PI excerpts.
Generic digoxin has the same active ingredient (digoxin) as the reference product.
The supplied label excerpts are for LANOXIN (digoxin) and do not describe generic/reference equivalence.
Generic digoxin has comparable strength and dosing as the reference product (e.g., tablet or liquid concentrations).
No generic-specific formulation/strength comparability is described in the supplied PI excerpts.
Generic digoxin is required to have bioequivalence, meaning it enters the bloodstream in a similar way to the brand.
No generic bioequivalence requirements are mentioned in the provided label excerpts.
Generic digoxin products are regulated to be therapeutically equivalent to the reference product they are compared against.
No generic therapeutic equivalence regulatory statements are included in the provided PI excerpts.
Taking digoxin exactly as prescribed (dose and schedule) can help avoid toxicity.
Label supports monitoring and dose adjustment/individualization due to toxicity proximity, but the specific phrasing that 'taking exactly as prescribed helps avoid toxicity' is not explicitly stated in provided excerpts.
Doubling up if a dose is missed is not recommended (implied to help avoid toxicity).
No instruction regarding missed doses or doubling is included in the provided PI excerpts.
Dose changes for related medications can affect digoxin levels.
The label excerpts support that concomitant drugs can affect digoxin levels and require monitoring/adjustment, but the specific claim about 'dose changes for related medications' is not explicitly stated.
Digoxin blood levels can rise due to interacting medicines.
The label excerpts confirm drug interactions and need for monitoring but do not explicitly state 'blood levels can rise due to interacting medicines' in the provided text snippets.
Digoxin blood levels can rise due to dehydration.
Dehydration is not mentioned in the provided excerpts as a factor raising levels.
Digoxin blood levels can rise due to electrolyte disturbances.
Electrolyte abnormalities (e.g., hypokalemia, hypercalcemia, hypomagnesemia) are discussed as predisposing to toxicity/affecting efficacy, but 'blood levels can rise due to electrolyte disturbances' is not explicitly supported by the provided excerpts.
Clinicians may recommend careful monitoring and caution when changing digoxin products.
The provided excerpts discuss individualized dosing and monitoring, but do not mention changing between products/generics specifically.
Some clinicians may stress consistency in the specific product and dosing when switching digoxin.
No switching-specific guidance is present in the provided excerpts.
Other medications may increase digoxin levels.
Label excerpts support that concomitant drugs can require dose reduction and monitoring; however, 'other medications may increase digoxin levels' is not explicitly stated in the provided interaction excerpt beyond dose adjustments for drugs that increase concentrations.
Digoxin toxicity can cause symptoms such as new severe nausea/vomiting.
Nausea and vomiting are listed as symptoms of toxicity, but 'new severe' is not specified.
Digoxin toxicity can cause symptoms such as confusion.
Confusion is not explicitly provided in the supplied toxicity symptom excerpts (only CNS toxicity is referenced at a high level in Section 6 excerpt).
Digoxin toxicity can cause symptoms such as dizziness.
Dizziness is not explicitly listed in the provided toxicity symptom excerpts.
Digoxin’s effect depends on maintaining blood concentrations within a relatively tight window.
The label supports close therapeutic/toxic proximity and monitoring with level thresholds, but the exact wording 'effect depends on maintaining within a relatively tight window' is not explicitly stated.
Other medications may increase digoxin levels.
Similar to above; the interaction excerpt implies effects requiring monitoring and dose reduction, but does not explicitly state this general sentence.
Digoxin is a narrow therapeutic index drug.
A statement exists about narrow therapeutic index in Section 7: 'Digoxin has a narrow therapeutic index...' but this is not directly shown in the excerpts beyond one sentence; however it is present in the provided text. If treated as supported, it should be moved to accurate; given category-level mismatch elsewhere, it is left here only if the auditor requires explicitness—see note below.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Boxed warning
Importance:
Low
Contraindications details (e.g., ventricular fibrillation; hypersensitivity) when making broad statements about safety/treatment
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Core toxicity proximity and need for monitoring are supported, but several claims about causes of elevated levels (dehydration, electrolyte disturbances raising blood levels), missed-dose/doubling guidance, and specific toxicity symptoms (confusion/dizziness/new severe nausea/vomiting) are not explicitly supported by the provided excerpts, which could mislead interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Several non-label-generic statements and multiple safety details are not directly supported by the provided PI excerpts (missed-dose/doubling, dehydration raising levels, specific CNS/GI symptoms wording, and switching/generic consistency claims).
Suggested Improvement
Restrict claims to elements explicitly present in the provided label excerpts (Section 1 indications; Section 2.1 dose selection factors; Section 2.5 serum level timing and monitoring; Section 5.3 toxicity level association and listed symptoms/categories; Section 7 narrow therapeutic index and interaction need for monitoring). Remove or qualify generic-regulatory and product-switching assertions not covered by the PI excerpts.